SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 1)
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of April 2020
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
This Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124, 333-199033, 333- 236064, 333-209037 and 333-220644), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On April 1, 2020, Can-Fite BioPharma Ltd. (the “Company”) filed a Current Report on Form 6-K announcing that it will hold a Special Meeting of Shareholders on April 21, 2020 at 4:00 P.M. (Israel time) at the Company’s offices in Petach-Tikva, Israel and attached a Notice and Proxy Statement and form of Proxy and Voting Instruction Card.
This Amendment No. 1 on Form 6-K/A is being furnished to amend and restate the Notice and Proxy Statement in order to correct the record date of the Special Meeting of Shareholders in the Notice to April 2, 2020. No other changes have been made to the Notice and Proxy Statement. In connection with the meeting, the Company furnishes the following documents:
|1.||A copy of the Notice and Proxy Statement with respect to the Company’s Special Meeting of Shareholders describing the proposal to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1;|
|2.||A form of Proxy whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2; and|
|3.||A form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.3.|
|99.1||Notice and Proxy Statement with respect to the Company’s Special Meeting of Shareholders|
|99.2||Proxy for holders of ordinary shares with respect to the Company’s Special Meeting of Shareholders|
|99.3||Voting Instruction Card for American Depositary Share holders with respect to the Company’s Special Meeting of Shareholders|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Can-Fite BioPharma Ltd.|
|Date: April 2, 2020||By:||/s/ Pnina Fishman|
|Chief Executive Officer|